INBS preliminary Q3 revenue $0.82M, up 80% YoY; nine-month revenue $2.38M, up 193%

INTELLIGENT BIO SOLUTIONS INC.

2024-Q3 EPS reported -$6.64 vs consensus -$5.41 ▼ miss (-22.8%)

Preliminary unaudited revenue $0.82M for fiscal Q3 ended March 31, 2024, up 80% vs. prior year.
Nine-month revenue $2.38M, up 193% YoY.
Cartridge sales up 17% and reader sales up 20% in Q3; highest quarterly cartridge sales since 2022 acquisition.
Nine-month cartridge sales up 25%, reader sales up 63% YoY.
Full financial results expected in Form 10-Q filed during week of May 6, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. reported the fiscal third quarter and nine months ended March 31, 2024 results: revenue $0.82 million.

Period: the fiscal third quarter and nine months ended March 31, 2024
Revenue: $0.82 million
Result: preliminary results

Exact text from the filing

today announced preliminary unaudited revenue results for the fiscal third quarter and nine months ended March 31, 2024. The Company expects approximate unaudited revenue of $0.82 million for the three months ended March 31, 2024, representing an increase of 80% compared to the same period the prior year, and approximate unaudited revenue of $2.38 million for the

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-015198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.